{"DataElement":{"publicId":"3110882","version":"1","preferredName":"Deep Vein Thrombosis Prevention Daily Quantity Type","preferredDefinition":"the type related to daily amount of a prophylaxis for blood clot (thrombus) in a deep vein in the thigh or leg.","longName":"3110874v1.0:3110875v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"3110874","version":"1","preferredName":"Deep Vein Thrombosis Prevention Daily Quantity","preferredDefinition":"information related to daily amount of a prophylaxis for blood clot (thrombus) in a deep vein in the thigh or leg.","longName":"3110871v1.0:3110872v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"3110871","version":"1","preferredName":"Deep Vein Thrombosis Prevention","preferredDefinition":"A blood clot (thrombus) in a deep vein in the thigh or leg.:An attempt to prevent disease.","longName":"C49343:C15405","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Deep Vein Thrombosis","conceptCode":"C49343","definition":"A blood clot in a deep vein, predominantly in the lower extremity, but may include the pelvis or upper extremity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Prevention","conceptCode":"C15405","definition":"An attempt to prevent disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"893E3629-2BA4-8A12-E040-BB89AD43792F","latestVersionIndicator":"Yes","beginDate":"2010-06-17","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-06-17","modifiedBy":"ONEDATA","dateModified":"2010-06-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3110872","version":"1","preferredName":"Daily Quantity","preferredDefinition":"Occurring or done each day.:Quantity; how much there is of something that you can measure.","longName":"C25473:C25256","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Daily","conceptCode":"C25473","definition":"Occurring or done each day.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Quantity","conceptCode":"C25256","definition":"How much there is of something that you can measure; the total amount or number.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"893E3629-2BB5-8A12-E040-BB89AD43792F","latestVersionIndicator":"Yes","beginDate":"2010-06-17","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-06-17","modifiedBy":"ONEDATA","dateModified":"2010-06-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008560","version":"1","preferredName":"Therapy Doses","preferredDefinition":"quantities of therapy or treatment.","longName":"TX_DOSES","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B30C55B6-50B5-1219-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-30","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"893E3629-2BC6-8A12-E040-BB89AD43792F","latestVersionIndicator":"Yes","beginDate":"2010-06-17","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-06-17","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3110875","version":"1","preferredName":"Deep Vein Thrombosis Prevention Daily Quantity Type","preferredDefinition":"the type or amount of medicine taken daily for deep vein thrombosis prophylaxis.","longName":"3110875v1.0","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"35","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Levonox 40mg","valueDescription":"Levonox 40mg","ValueMeaning":{"publicId":"3110876","version":"1","preferredName":"Levonox 40mg","longName":"3110876","preferredDefinition":"Levonox 40mg","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"893E3629-2BEE-8A12-E040-BB89AD43792F","latestVersionIndicator":"Yes","beginDate":"2010-06-17","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-06-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"893E3629-2C07-8A12-E040-BB89AD43792F","beginDate":"2010-06-17","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-06-17","modifiedBy":"ONEDATA","dateModified":"2010-06-17","deletedIndicator":"No"},{"value":"Aspirin (Other Dose)","valueDescription":"Aspirin (Other Dose)","ValueMeaning":{"publicId":"3110877","version":"1","preferredName":"Aspirin (Other Dose)","longName":"3110877","preferredDefinition":"Aspirin (Other Dose)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"893E3629-2C11-8A12-E040-BB89AD43792F","latestVersionIndicator":"Yes","beginDate":"2010-06-17","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-06-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"893E3629-2C2A-8A12-E040-BB89AD43792F","beginDate":"2010-06-17","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-06-17","modifiedBy":"ONEDATA","dateModified":"2010-06-17","deletedIndicator":"No"},{"value":"325mg","valueDescription":"325mg (Aspirin)","ValueMeaning":{"publicId":"3110878","version":"1","preferredName":"325mg (Aspirin)","longName":"3110878","preferredDefinition":"325mg (Aspirin)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"893E3629-2C34-8A12-E040-BB89AD43792F","latestVersionIndicator":"Yes","beginDate":"2010-06-17","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-06-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"893E3629-2C4D-8A12-E040-BB89AD43792F","beginDate":"2010-06-17","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-06-17","modifiedBy":"ONEDATA","dateModified":"2010-06-17","deletedIndicator":"No"},{"value":"Coumadin","valueDescription":"Warfarin Sodium","ValueMeaning":{"publicId":"3110880","version":"1","preferredName":"Warfarin Sodium","longName":"3110880","preferredDefinition":"The sodium salt form of warfarin, a coumarin and a vitamin K antagonist, with anticoagulant activity. Warfarin sodium inhibits both vitamin K and vitamin K epoxide reductases, thereby interfering with the cyclic interconversion of vitamin K epoxide to its reduced form, vitamin KH2. Vitamin KH2 is a cofactor for the carboxylation of glutamate residues on the N-terminal regions of vitamin K-dependent proteins.  As a result, maturation of vitamin K-dependent coagulation factors II, VII, IX, and X and anticoagulant proteins C and S is inhibited. Without these coagulation factors, thrombogenesis and blood clot formation are prevented.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Warfarin Sodium","conceptCode":"C1658","definition":"The sodium salt form of warfarin, a coumarin and a vitamin K antagonist, with anticoagulant activity. Warfarin sodium inhibits both vitamin K and vitamin K epoxide reductases, thereby interfering with the cyclic interconversion of vitamin K epoxide to its reduced form, vitamin KH2. Vitamin KH2 is a cofactor for the carboxylation of glutamate residues on the N-terminal regions of vitamin K-dependent proteins.  As a result, maturation of vitamin K-dependent coagulation factors II, VII, IX, and X and anticoagulant proteins C and S is inhibited. Without these coagulation factors, thrombogenesis and blood clot formation are prevented.","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"893E3629-2C5A-8A12-E040-BB89AD43792F","latestVersionIndicator":"Yes","beginDate":"2010-06-17","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-06-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"893E3629-2C73-8A12-E040-BB89AD43792F","beginDate":"2010-06-17","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-06-17","modifiedBy":"ONEDATA","dateModified":"2010-06-17","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008560","version":"1","preferredName":"Therapy Doses","preferredDefinition":"quantities of therapy or treatment.","longName":"TX_DOSES","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B30C55B6-50B5-1219-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-30","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"893E3629-2BD8-8A12-E040-BB89AD43792F","latestVersionIndicator":"Yes","beginDate":"2010-06-17","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-06-17","modifiedBy":"ALAIS","dateModified":"2010-06-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Daily dose prescribed","type":"Preferred Question Text","description":"Daily dose prescribed","url":null,"context":"CTEP"}],"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"893E3629-2C7D-8A12-E040-BB89AD43792F","latestVersionIndicator":"Yes","beginDate":"2010-06-17","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-06-17","modifiedBy":"ALAIS","dateModified":"2010-06-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}